La información sobre este estudio está en inglés.
Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.
LY3002813 for Early Alzheimer's Disease (TRAILBLAZER-ALZ)
Start: December 18, 2017
End: September 21, 2021
Enrollment: 266
What Is This Study About?
TRAILBLAZER-ALZ aims to evaluate the safety, tolerability, and efficacy of the investigational drug LY3002813 in early symptomatic Alzheimer's disease.
Do I Qualify To Participate in This Study?
Minimum Age: 60 Years
Maximum Age: 85 Years
Must have:
- Gradual and progressive change in memory function for 6 months or longer
- Mini-Mental State Examination score of 20 to 28 or a flortaucipir positron emission tomography (PET) scan within past 6 months that meets criteria
- Meet criteria for 18F flortaucipir and 18F florbetapir PET scans
Must NOT have:
- History of long QT syndrome
- Use of a stable dose of an acetylcholinesterase inhibitor, such as donepezil (Aricept), galantamine (Razadyne), and rivastigmine (Exelon), and/or memantine (Namenda) for less than 2 months before randomization
- Inability to undergo magnetic resonance imaging
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Who Is the General Study Contact?
For more information about this study or study sites, visit the TRAILBLAZER-ALZ study website, email clinicaltrials.gov@lilly.com, or call 1-877-285-4559 or 1-317-615-4559 Monday-Friday 9 a.m. to 5 p.m. Eastern.
Need Help?
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Who Sponsors This Study?
Lead: Eli Lilly and Company
Source: ClinicalTrials.gov ID: NCT03367403